EBS250110C11000
- 0.10
- 0.000.00%
Emergent BioSolutions Newsroom
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $15
Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Express News | Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense With Biothrax® (Anthrax Vaccine Adsorbed)
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
Emergent BioSolutions (NYSE:EBS) Shareholder Returns Have Been Solid, Earning 285% in 1 Year
Why Emergent BioSolutions Stock Blasted Higher Today
Sector Update: Health Care Stocks Lower Monday Afternoon
Crude Oil Gains 1%; Chicago PMI Falls In December
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
HC Wainwright & Co. Initiates Coverage On Emergent BioSolutions With Buy Rating, Announces Price Target of $15
Emergent BioSolutions Analyst Ratings
H.C. Wainwright Initiates Emergent BioSolutions(EBS.US) With Buy Rating, Announces Target Price $15
Express News | Emergent BioSolutions Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $15
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
Sector Update: Health Care
Emergent BioSolutions Wins $50 Million Contract Option for Cyfendus; Shares Rise
Express News | Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
Express News | Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted)